API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Review of program led reassessment of benefit-risk ratio in four potential indication for investigational P2X3 receptor antagonist, BAY 1817080 (eliapixant) potential indications in endometriosis, refractory chronic cough, overactive bladder and diabetic neuropathic pain.
Lead Product(s): Eliapixant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: BAY 1817080
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Evotec
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2022